{
  "id": 6278950,
  "title": "STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies",
  "url": "https://urgent.news/2026/09/08/stat-astrazenecas-experimental-copd-treatment-posts-strong-results-in",
  "topic": "science",
  "section": "Science",
  "published": "2026-09-08T11:45:00.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/09/08/astrazeneca-tozorakimab-copd-exacerbations-titania-oberon/"
  },
  "original_language": "en",
  "account": "AstraZeneca's experimental COPD treatment, called tozorakimab, has shown strong results in late-stage trials, potentially offering a new option to millions of patients suffering from the debilitating lung condition, according to data released on Tuesday. The Phase 3 trials of tozo, an injectable drug, also demonstrated a reassuring victory for AstraZeneca, which has recently faced some missed opportunities in trial results. Analysts and the company predict that \"tozo\" could generate billions in annual sales if approved, both for COPD, the third-leading cause of death globally, and other conditions like asthma. The trials revealed that tozo reduced COPD exacerbations, or sudden worsenings of the disease requiring medical care, by approximately 30% across all patients over a year. This finding makes tozo competitive with other recent COPD treatments. However, the trials included participants not eligible for other new drugs, potentially giving AstraZeneca a large segment of the market to itself.",
  "summary": "An experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market to itself.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}